Evidence map›Paper›PMID 39487131›Full record

ArticleNature communications2024

ChromaFold predicts the 3D contact map from single-cell chromatin accessibility.

Vianne R Gao, Rui Yang, Arnav Das, Renhe Luo, Hanzhi Luo, Dylan R McNally, Ioannis Karagiannidis, Martin A Rivas, Zhong-Min Wang, Darko Barisic and 14 more

Erratum issuedAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Recipes and ingredients for deep learning models of 3D genome folding.Current opinion in genetics & development · 2025
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Vianne R GaoComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rui YangComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9358-9907
Arnav DasUniversity of Washington, Seattle, WA, USA.
Renhe LuoDevelopmental Biology Program, Sloan Kettering Institute, New York, NY, USA.ORCID 0009-0008-1470-4726
Hanzhi LuoMolecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dylan R McNallyCaryl and Israel Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Ioannis KaragiannidisDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Martin A RivasDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-9603-6897
Zhong-Min WangHoward Hughes Medical Institute and Immunology Program, Sloan Kettering Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Darko BarisicDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0001-7007-9138
Alireza KarbalaygharehComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4308-2582
Wilfred WongComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1363-5235
Yingqian A ZhanCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3548-9227
Christopher R ChinDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-2140-3197
William S NobleUniversity of Washington, Seattle, WA, USA.ORCID 0000-0001-7283-4715
Jeff A BilmesUniversity of Washington, Seattle, WA, USA.
Effie Apostolou *Joan and Sanford I. Weill Department of Medicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-8111-0863
Michael G Kharas *Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-1165-6991
Wendy Béguelin *Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-4894-9229
Aaron D Viny *Departments of Medicine, Division of Hematology & Oncology, and of Genetics & Development, Columbia Stem Cell Initiative, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-7039-0110
Danwei Huangfu *Developmental Biology Program, Sloan Kettering Institute, New York, NY, USA.ORCID 0000-0002-1145-6199
Alexander Y Rudensky *Howard Hughes Medical Institute and Immunology Program, Sloan Kettering Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1280-2898
Ari M Melnick *Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-8074-2287
Christina S LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lesliec@mskcc.org.ORCID 0000-0002-4571-5910

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Genomic control of gene regulatory networks governing early human lineagedecisionsU01HG012051 · NHGRI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael A Beer, ANNA-KATERINA HADJANTONAKIS · 2021 to 2026
$8.3M
Mechanisms of epitranscriptomic regulation in cancerR01CA186702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY, Michael Kharas · 2014 to 2026
$8.0M
Deciphering the Genomics of Gene Network Regulation of T Cell and Fibroblast States in Autoimmune InflammationU01HG012103 · NHGRI · SLOAN-KETTERING INST CAN RESEARCH · PI Christina S Leslie, Alexander Y Rudensky · 2021 to 2026
$7.5M
Uncovering the role for MSI2 network in hematopoietic stem cellsR01DK101989 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas, Vijay Ganesh Sankaran · 2014 to 2026
$6.2M
Characterizing the MSI2 network in leukemiaR01CA193842 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL · 2015 to 2025
$4.1M
Discovery of diabetes-relevant β cell enhancers through 4D enhancer mapping, integrative analysis, and large-scale CRISPRi perturbation screensU01DK128852 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI APOSTOLOU, EFFIE, HUANGFU, DANWEI · 2020 to 2024
$3.5M
The gut endoderm: origin, formation and fateR01DK127821 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI ANNA-KATERINA HADJANTONAKIS · 2021 to 2026
$3.4M
Identification of therapeutic targets for leukemia stem cells in AML-iPSC modelsR01CA225231 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KHARAS, MICHAEL, PAPAPETROU, EIRINI · 2018 to 2022
$3.2M
Interrogation of the oxidative-stress-induced leukemia program in vivo usingmetabolic imagingR01CA283578 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari, Michael Kharas · 2023 to 2026
$3.0M
Molecular and genetic analysis of novel Slicer-dependent miRNA pathways in bloodR01HL135564 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL, LAI, ERIC C · 2017 to 2020
$2.9M
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in LymphomaR01CA274249 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas · 2023 to 2026
$2.8M
NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA246080NCI NIH HHS R01 CA186702NCI NIH HHS R01 CA193842NCI NIH HHS R01 CA225231NCI NIH HHS R01 CA270245NCI NIH HHS R01 CA274249NCI NIH HHS R01 CA283578NHGRI NIH HHS U01 HG012051NHGRI NIH HHS U01 HG012103NHLBI NIH HHS R01 HL135564NIDDK NIH HHS K99 DK128602NIDDK NIH HHS R01 DK101989NIDDK NIH HHS R01 DK127821NIDDK NIH HHS U01 DK128852U.S. Department of Health & Human Services | National Institutes of Health (NIH) DK128852U.S. Department of Health & Human Services | National Institutes of Health (NIH) HG012103
6 · The paper itself

Abstract

Identifying cell-type-specific 3D chromatin interactions between regulatory elements can help decipher gene regulation and interpret disease-associated non-coding variants. However, achieving this resolution with current 3D genomics technologies is often infeasible given limited input cell numbers. We therefore present ChromaFold, a deep learning model that predicts 3D contact maps, including regulatory interactions, from single-cell ATAC sequencing (scATAC-seq) data alone. ChromaFold uses pseudobulk chromatin accessibility, co-accessibility across metacells, and a CTCF motif track as inputs and employs a lightweight architecture to train on standard GPUs. Trained on paired scATAC-seq and Hi-C data in human samples, ChromaFold accurately predicts the 3D contact map and peak-level interactions across diverse human and mouse test cell types. Compared to leading contact map prediction models that use ATAC-seq and CTCF ChIP-seq, ChromaFold achieves state-of-the-art performance using only scATAC-seq. Finally, fine-tuning ChromaFold on paired scATAC-seq and Hi-C in a complex tissue enables deconvolution of chromatin interactions across cell subpopulations.

Indexed as

ChromatinSingle-Cell AnalysisAnimalsCCCTC-Binding FactorChromatin Immunoprecipitation SequencingDeep LearningHumansMiceCCCTC-Binding FactorChromatin

Identifiers

PMID39487131
PMCPMC11530433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.